CardAP cells
Chronic Myocardial Insufficiency (Heart Failure)
Pre-clinicalActive
Key Facts
Indication
Chronic Myocardial Insufficiency (Heart Failure)
Phase
Pre-clinical
Status
Active
Company
About CellServe
CellServe is a private, pre-revenue biotech developing an autologous cell therapy for chronic heart failure. Its core technology, CardAP cells, involves isolating, expanding, and re-transplanting a patient's own heart-derived cells with the aim of improving cardiac function and offering a less invasive alternative to transplantation. The company is in the pre-clinical/early clinical development stage, positioning itself as a potential first curative therapy in a large, underserved market with significant mortality.
View full company profile